BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.
- Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.
- The data was recently presented at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark.
- There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case.
- Based on these results, planning is underway for a Phase II study that is expected to begin enrolling patients in H1 (first half) 2024.